A_phase_I_study_of_high-dose_ifosfamide_and_escalating_doses_of_carboplatin_with_autologous_bone_marrow_support._The_dose-limiting_toxicity_in_two_separate_phase_I_trials_of_the_high-dose_single_agents_ifosfamide_and_carboplatin_was_renal_insufficiency_at_18_g/m2_and_hepatic_and_ototoxicity_at_2,400_mg/m2,_respectively._In_this_phase_I_study,_16_adults_were_treated_with_ifosfamide_at_75%_of_the_single-agent_maximum-tolerated_dose_(MTD)_(12_g/m2)_and_escalating_doses_of_carboplatin_(400_to_1,600_mg/m2)_to_determine_the_nonhematologic_dose-limiting_toxicity_and_the_maximum-tolerated_dose_of_the_combination._Both_drugs_as_well_as_mesna_for_uroprotection_were_given_by_continuous_infusion_over_4_days_with_an_additional_day_of_mesna_(total_dose_per_course,_15_g/m2)._Autologous_bone_marrow_support_was_stipulated_for_subsequent_dose_levels_once_granulocytes_remained_less_than_500/microL_for_more_than_14_days_in_two_of_three_to_five_patients_entered_at_a_given_dose_level._Autologous_bone_marrow_support_was_used_at_doses_above_the_400_mg/m2_carboplatin_dose_level._At_the_maximum-tolerated_dose_level_of_1,600_mg/m2_of_carboplatin,_renal_toxicity_precluded_further_dose_escalation._Of_the_five_patients_entered_at_this_dose_level,_reversible_creatinine_elevation_greater_than_2_mg/dL_(median_peak,_2.6_mg/dL)_was_observed_in_three_patients,_and_irreversible_renal_failure_occurred_in_an_additional_patient_(peak_creatinine,_6.9_mg/dL._Transient_gross_hematuria_appeared_more_common_with_the_combination_than_with_ifosfamide_alone._Two_patients_developed_severe_somnolence_and_confusion_associated_with_a_rising_creatinine._There_were_two_complete_(CRs)_and_four_partial_responses_(PRs)_in_14_heavily_pretreated_assessable_patients_(including_four_partial_or_complete_responses_in_eight_assessable_patients_with_advanced_refractory_sarcoma,_and_one_CR_in_two_patients_with_germ_cell_carcinoma)._Carboplatin_and_ifosfamide_appear_to_have_overlapping_renal_toxicity._Nevertheless,_carboplatin_and_ifosfamide_can_be_combined_at_80%_and_75%_of_the_single-agent_maximum-tolerated_doses,_respectively,_with_acceptable_nonhematologic_toxicity._Ifosfamide_and_carboplatin_are_an_attractive_core_combination_for_further_studies_in_the_treatment_of_sarcoma,_germ_cell,_ovarian,_and_lung_carcinomas.